Table 1 Included randomized controlled trials.

From: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

				Control group
Study	N	Age	Male (%)	Asp	TP	GP	Triple group	Heparin	Length of treatment	Length of follow-up (months)	Quality*
NSTE-ACS
ADVANCE[41]	202	69	68	√	√		Tirofiban	√	48 h	6	A
ELISA-2[42]	328	64	71	√	√		Tirofiban	-	12 h	1	A
ISAR-REACT-2[43]	2,022	66	75	√	√		Abciximab	√	12 h	1	A
PROTECT-TIMI-30[44]	857	60	67	√	√		Eptifibatide	√	24 h	48 h	A
STEMI
ADMIRAL[45]	300	61	82	√	√		Abciximab	√	12 h	6	A
ACE[46]	400	64	77	√	√		Abciximab	√	12 h	6	A
CADILLAC [47]	2082	60	73	√	√		Abciximab	√	12 h	6	B
Ernst/1[48]	60	61	74	√	√		Abciximab	√	12 h	1	B
Ernst/2[48]	60	60	82	√	√		Tirofiban	√	12 h	1	B
Ernst/3[48]	59	61	76	√	√		Tirofiban high dose	√	12 h	1	B
ISAR 2[30]	401	61	76	√	√		Abciximab	√	12 h	1	B
Neumann[31]	200	60	77	√	√		Abciximab	√	12 h	1	B
Petronio[49]	31	57	87	√	√		Abciximab	√	12 h	1	B
Kim[50]	60	63	70	√	√		Cilostazol	√	1 month	1	B
Elective PCI
Claeys[51]	200	67	70	√	√		Abciximab	√	12 h	6	B
EPISTENT[52]	1,603	59	75	√	√		Abciximab	√	13 h	1	A
ESPRIT[35]	2,064	62	73	√	√		Eptifibatide	√	24 h	1	B
ISAR-REACT[53]	2,159	66	77	√	√		Abciximab	√	12 h	1	A
ISAR-SMART-2[54]	502	66	73	√	√		Abciximab	√	12 h	12	A
ISAR-SWEET[55]	701	68	75	√	√		Abciximab	√	12 h	12	A
TOPSTAR[56]	96	65	75	√	√		tirofiban	√	42 h	9	A
MR PCI/1[57]	60	61	85	√	-	√	Clopidogrel	√	30 days	1	A
MR PCI/2[57]	60	56	85	√	-	√	Clopidogrel	√	30 days	1	A
DECLARE-Long[58]	500	61	64	√	√		Cilostazol	-	6 months	6	A
DECLARE-DIABETES[59]	400	61	58	√	√		Cilostazol	-	6 months	6	A
Min[60]	59	62	66	√	√		Cilostazol	√	1 month	6	A
CREST[61]	705	60	74	√	√		Cilostazol	-	6 months	6	A
Han[62]	1212	60	73	√	√		Cilostazol	-	6 months	12	A

*Quality scale: A, true randomization and allocation concealed; B, process of randomization not given and concealment of allocation unclear.
Asp, aspirin; GP, glycoprotein IIb/IIIa receptor antagonists (abciximab, tirofiban, eptifibatide); MI, myocardial infarction; NSTEACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary interventions; TP, thienopyridine (clopidogrel, ticlopidine).

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com